Extranodal NK-T-cell lymphoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{RG}} | {{CMG}}; {{AE}} {{RG}} | ||
==Overview== | ==Overview== | ||
The predominant therapy for extranodal NK-T-cell lymphoma is [[radiation therapy]]. | The predominant therapy for extranodal NK-T-cell lymphoma is [[radiation therapy]]. Adjudicative [[chemotherapy]] and [[stem cell transplant]] may be required. | ||
==Medical Therapy== | ==Medical Therapy== | ||
* The predominant therapy for extranodal NK-T-cell lymphoma is [[radiation therapy]]. | * The predominant therapy for extranodal NK-T-cell lymphoma is [[radiation therapy]]. Adjudicative [[chemotherapy]] and [[stem cell transplant]] may be required.<ref name="canadiancancer" /> | ||
* Therapy of extranodal NK/T cell lymphoma depends on staging of the tumor:<ref name="DreylingThieblemont2013">{{cite journal|last1=Dreyling|first1=M.|last2=Thieblemont|first2=C.|last3=Gallamini|first3=A.|last4=Arcaini|first4=L.|last5=Campo|first5=E.|last6=Hermine|first6=O.|last7=Kluin-Nelemans|first7=J. C.|last8=Ladetto|first8=M.|last9=Le Gouill|first9=S.|last10=Iannitto|first10=E.|last11=Pileri|first11=S.|last12=Rodriguez|first12=J.|last13=Schmitz|first13=N.|last14=Wotherspoon|first14=A.|last15=Zinzani|first15=P.|last16=Zucca|first16=E.|title=ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma|journal=Annals of Oncology|volume=24|issue=4|year=2013|pages=857–877|issn=1569-8041|doi=10.1093/annonc/mds643}}</ref><ref name="IsobeUno2006">{{cite journal|last1=Isobe|first1=Koichi|last2=Uno|first2=Takashi|last3=Tamaru|first3=Jun-ichi|last4=Kawakami|first4=Hiroyuki|last5=Ueno|first5=Naoyuki|last6=Wakita|first6=Hisashi|last7=Okada|first7=Jun-ichi|last8=Itami|first8=Jun|last9=Ito|first9=Hisao|title=Extranodal natural killer/T-cell lymphoma, nasal type|journal=Cancer|volume=106|issue=3|year=2006|pages=609–615|issn=0008-543X|doi=10.1002/cncr.21656}}</ref><ref name="LiYao2006">{{cite journal|last1=Li|first1=Ye-Xiong|last2=Yao|first2=Bo|last3=Jin|first3=Jing|last4=Wang|first4=Wei-Hu|last5=Liu|first5=Yue-Ping|last6=Song|first6=Yong-Wen|last7=Wang|first7=Shu-Lian|last8=Liu|first8=Xin-Fan|last9=Zhou|first9=Li-Qiang|last10=He|first10=Xiao-Hui|last11=Lu|first11=Ning|last12=Yu|first12=Zi-Hao|title=Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma|journal=Journal of Clinical Oncology|volume=24|issue=1|year=2006|pages=181–189|issn=0732-183X|doi=10.1200/JCO.2005.03.2573}}</ref> | * Therapy of extranodal NK/T cell lymphoma depends on staging of the tumor:<ref name="DreylingThieblemont2013">{{cite journal|last1=Dreyling|first1=M.|last2=Thieblemont|first2=C.|last3=Gallamini|first3=A.|last4=Arcaini|first4=L.|last5=Campo|first5=E.|last6=Hermine|first6=O.|last7=Kluin-Nelemans|first7=J. C.|last8=Ladetto|first8=M.|last9=Le Gouill|first9=S.|last10=Iannitto|first10=E.|last11=Pileri|first11=S.|last12=Rodriguez|first12=J.|last13=Schmitz|first13=N.|last14=Wotherspoon|first14=A.|last15=Zinzani|first15=P.|last16=Zucca|first16=E.|title=ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma|journal=Annals of Oncology|volume=24|issue=4|year=2013|pages=857–877|issn=1569-8041|doi=10.1093/annonc/mds643}}</ref><ref name="IsobeUno2006">{{cite journal|last1=Isobe|first1=Koichi|last2=Uno|first2=Takashi|last3=Tamaru|first3=Jun-ichi|last4=Kawakami|first4=Hiroyuki|last5=Ueno|first5=Naoyuki|last6=Wakita|first6=Hisashi|last7=Okada|first7=Jun-ichi|last8=Itami|first8=Jun|last9=Ito|first9=Hisao|title=Extranodal natural killer/T-cell lymphoma, nasal type|journal=Cancer|volume=106|issue=3|year=2006|pages=609–615|issn=0008-543X|doi=10.1002/cncr.21656}}</ref><ref name="LiYao2006">{{cite journal|last1=Li|first1=Ye-Xiong|last2=Yao|first2=Bo|last3=Jin|first3=Jing|last4=Wang|first4=Wei-Hu|last5=Liu|first5=Yue-Ping|last6=Song|first6=Yong-Wen|last7=Wang|first7=Shu-Lian|last8=Liu|first8=Xin-Fan|last9=Zhou|first9=Li-Qiang|last10=He|first10=Xiao-Hui|last11=Lu|first11=Ning|last12=Yu|first12=Zi-Hao|title=Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma|journal=Journal of Clinical Oncology|volume=24|issue=1|year=2006|pages=181–189|issn=0732-183X|doi=10.1200/JCO.2005.03.2573}}</ref><ref name="KimYang2014">{{cite journal|last1=Kim|first1=Seok Jin|last2=Yang|first2=Deok-Hwan|last3=Kim|first3=Jin Seok|last4=Kwak|first4=Jae-Yong|last5=Eom|first5=Hyeon-Seok|last6=Hong|first6=Dae Sik|last7=Won|first7=Jong Ho|last8=Lee|first8=Jae Hoon|last9=Yoon|first9=Dok Hyun|last10=Cho|first10=Jaeho|last11=Nam|first11=Taek-Keun|last12=Lee|first12=Sang-wook|last13=Ahn|first13=Yong Chan|last14=Suh|first14=Cheolwon|last15=Kim|first15=Won Seog|title=Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study|journal=Annals of Hematology|volume=93|issue=11|year=2014|pages=1895–1901|issn=0939-5555|doi=10.1007/s00277-014-2137-6}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
| Line 18: | Line 18: | ||
!Chemotherapy regimen | !Chemotherapy regimen | ||
!Alternative | !Alternative | ||
!Over 69 /severe organ damage/low lymphocyte | |||
|- | |- | ||
|I(E) | |I(E) | ||
| Line 25: | Line 26: | ||
|50 Gy RT | |50 Gy RT | ||
|DeVIC∞ | |DeVIC∞ | ||
| | |40 Gy RT + weekly Cisplatin | ||
| - | |||
|- | |- | ||
|II(E) | |II(E) | ||
|Stage I(E) +One or more of † involvments | |Stage I(E) +One or more of † involvments | ||
|upper aerodigestive tract | |upper aerodigestive tract | ||
| | |Combined modality therapy | ||
| | |50 Gy RT | ||
| | |DeVIC | ||
| | |40 Gy RT + weekly Cisplatin | ||
| - | |||
|- | |- | ||
|III(E)• | |III(E)• | ||
|Stage I (E) + Cervical lymph node involvment + infradiaphragmatic lymph node / Involvment of spleen | |Stage I (E) + Cervical lymph node involvment + infradiaphragmatic lymph node / Involvment of spleen | ||
|Systemic | |Systemic / | ||
| | Disseminated | ||
| | |SMILE៛ | ||
| | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |||
| | | | ||
|Less intensive L-asparaginase-containing chemotherapy | |||
|- | |- | ||
|IV | |IV | ||
|Stage I(E) +isolated distant involvment | |Stage I(E) +isolated distant involvment | ||
|Systemic | |Systemic / | ||
| | Disseminated | ||
| | |SMILE | ||
| | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |||
| | | | ||
|Less intensive L-asparaginase-containing chemotherapy | |||
|} | |} | ||
†: Cervical lymph node involvement / Involvment of other superdiaphragmatic lymph node regions / Isolated involvment of additional sites in the head and neck | †: Cervical lymph node involvement / Involvment of other superdiaphragmatic lymph node regions / Isolated involvment of additional sites in the head and neck | ||
| Line 58: | Line 65: | ||
∞:Dexamethasone, Etoposide, Ifosfamide, Carboplatin. | ∞:Dexamethasone, Etoposide, Ifosfamide, Carboplatin. | ||
៛: Dexamethasone. Methotrexate, Ifosfamide, L-asparaginase, Etoposide | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | {| style="border: 0px; font-size: 90%; margin: 3px;" align="center" | ||
|+'''Treatment of extranodal NK-T-cell lymphoma<ref name="canadiancancer">Extranodal NK/T-cell lymphoma, nasal type. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/extranodal-nk-t-cell-lymphoma-nasal-type/?region=on. Accessed on February 02, 2016 </ref>''' | |+'''Treatment of extranodal NK-T-cell lymphoma<ref name="canadiancancer">Extranodal NK/T-cell lymphoma, nasal type. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/extranodal-nk-t-cell-lymphoma-nasal-type/?region=on. Accessed on February 02, 2016 </ref>''' | ||
Revision as of 14:10, 30 August 2019
|
Extranodal NK-T-cell lymphoma Microchapters |
|
Differentiating Extranodal NK-T-cell lymphoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Extranodal NK-T-cell lymphoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Extranodal NK-T-cell lymphoma medical therapy |
|
Risk calculators and risk factors for Extranodal NK-T-cell lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ramyar Ghandriz MD[2]
Overview
The predominant therapy for extranodal NK-T-cell lymphoma is radiation therapy. Adjudicative chemotherapy and stem cell transplant may be required.
Medical Therapy
- The predominant therapy for extranodal NK-T-cell lymphoma is radiation therapy. Adjudicative chemotherapy and stem cell transplant may be required.[1]
- Therapy of extranodal NK/T cell lymphoma depends on staging of the tumor:[2][3][4][5]
| Stage | Involvment | Common involvement place | Preferred therapy method | Radiation dosage | Chemotherapy regimen | Alternative | Over 69 /severe organ damage/low lymphocyte |
|---|---|---|---|---|---|---|---|
| I(E) | Single extranodal involvement | upper aerodigestive tract | Combined modality therapy‡ | 50 Gy RT | DeVIC∞ | 40 Gy RT + weekly Cisplatin | - |
| II(E) | Stage I(E) +One or more of † involvments | upper aerodigestive tract | Combined modality therapy | 50 Gy RT | DeVIC | 40 Gy RT + weekly Cisplatin | - |
| III(E)• | Stage I (E) + Cervical lymph node involvment + infradiaphragmatic lymph node / Involvment of spleen | Systemic /
Disseminated |
SMILE៛ | - | - | Less intensive L-asparaginase-containing chemotherapy | |
| IV | Stage I(E) +isolated distant involvment | Systemic /
Disseminated |
SMILE | - | - | Less intensive L-asparaginase-containing chemotherapy |
†: Cervical lymph node involvement / Involvment of other superdiaphragmatic lymph node regions / Isolated involvment of additional sites in the head and neck
•: Rare
‡: Combined modality therapy is radiation therapy with concurrent chemotherapy
∞:Dexamethasone, Etoposide, Ifosfamide, Carboplatin.
៛: Dexamethasone. Methotrexate, Ifosfamide, L-asparaginase, Etoposide
| Therapy | Description |
|---|---|
| Radiation therapy |
|
| Chemotherapy |
|
| Stem cell transplant |
|
References
- ↑ 1.0 1.1 Extranodal NK/T-cell lymphoma, nasal type. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/extranodal-nk-t-cell-lymphoma-nasal-type/?region=on. Accessed on February 02, 2016
- ↑ Dreyling, M.; Thieblemont, C.; Gallamini, A.; Arcaini, L.; Campo, E.; Hermine, O.; Kluin-Nelemans, J. C.; Ladetto, M.; Le Gouill, S.; Iannitto, E.; Pileri, S.; Rodriguez, J.; Schmitz, N.; Wotherspoon, A.; Zinzani, P.; Zucca, E. (2013). "ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma". Annals of Oncology. 24 (4): 857–877. doi:10.1093/annonc/mds643. ISSN 1569-8041.
- ↑ Isobe, Koichi; Uno, Takashi; Tamaru, Jun-ichi; Kawakami, Hiroyuki; Ueno, Naoyuki; Wakita, Hisashi; Okada, Jun-ichi; Itami, Jun; Ito, Hisao (2006). "Extranodal natural killer/T-cell lymphoma, nasal type". Cancer. 106 (3): 609–615. doi:10.1002/cncr.21656. ISSN 0008-543X.
- ↑ Li, Ye-Xiong; Yao, Bo; Jin, Jing; Wang, Wei-Hu; Liu, Yue-Ping; Song, Yong-Wen; Wang, Shu-Lian; Liu, Xin-Fan; Zhou, Li-Qiang; He, Xiao-Hui; Lu, Ning; Yu, Zi-Hao (2006). "Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma". Journal of Clinical Oncology. 24 (1): 181–189. doi:10.1200/JCO.2005.03.2573. ISSN 0732-183X.
- ↑ Kim, Seok Jin; Yang, Deok-Hwan; Kim, Jin Seok; Kwak, Jae-Yong; Eom, Hyeon-Seok; Hong, Dae Sik; Won, Jong Ho; Lee, Jae Hoon; Yoon, Dok Hyun; Cho, Jaeho; Nam, Taek-Keun; Lee, Sang-wook; Ahn, Yong Chan; Suh, Cheolwon; Kim, Won Seog (2014). "Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study". Annals of Hematology. 93 (11): 1895–1901. doi:10.1007/s00277-014-2137-6. ISSN 0939-5555.